LINDSEY EDWARDS: Open Payments
NPI 1376295089 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,139 in 66 payments from 19 companies in 2025. Trend: 2023 $191 · 2024 $608 · 2025 $1,139
Food & beverage: $1,139
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $170 |
| Astellas Pharma US Inc | 7 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $128 |
| Lilly USA, LLC | 11 | $125 |
| AstraZeneca Pharmaceuticals LP | 5 | $83 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| PFIZER INC. | 4 | $65 |
| Exact Sciences Corporation | 2 | $31 |
| Boston Scientific Corporation | 2 | $29 |
Products named: Veozah, Kerendia, CAPLYTA, MOUNJARO, TRELEGY ELLIPTA, AIRSUPRA, Ozempic, KISUNLA.
Industry payments across IN — which companies pay providers there.
